Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Public ClinicalTrials.gov record NCT04309084. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Study identification
- NCT ID
- NCT04309084
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celularity Incorporated
- Industry
- Enrollment
- 29 participants
Conditions and interventions
Conditions
- Analgesics
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Blood Protein Disorders
- Cardiovascular Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorder
- Immune System Diseases
- Immunoproliferative Disorders
- Lymphoproliferative Disorders
- Multiple Myeloma
- Neoplasm, Plasma Cell
- Neoplasms
- Neoplasms by Histologic Type
- Paraproteinemias
- Peripheral Nervous System Agents
- Physiological Effects of Drugs
- Sensory System Agents
- Vascular Diseases
Interventions
- CYNK-001 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 11, 2020
- Primary completion
- Jan 30, 2023
- Completion
- Apr 29, 2023
- Last update posted
- Feb 15, 2023
2020 – 2023
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Roswell Park Comprehensive Cancer Institute | Buffalo | New York | 14203 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04309084, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 15, 2023 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04309084 live on ClinicalTrials.gov.